3-iodobenzylguanidine has been researched along with Parkinsonian Disorders in 38 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (28.95) | 29.6817 |
2010's | 25 (65.79) | 24.3611 |
2020's | 2 (5.26) | 2.80 |
Authors | Studies |
---|---|
Ikeda, T; Ikenoshita, S; Masuda, T; Nakahara, K; Sakamoto, F; Shiraishi, S; Yamashita, S | 1 |
Hashimoto, M; Ito, D; Iwabuchi, Y; Jinzaki, M; Kameyama, M; Matsusaka, Y; Narimatsu, H; Seki, M; Tabuchi, H; Yamada, Y | 1 |
Eriguchi, M; Fujioka, S; Hara, H; Hattori, N; Houzen, H; Li, Y; Mishima, T; Nishioka, K; Sato, K; Shiomi, K; Tsuboi, Y; Yabe, I | 1 |
Harada, M; Izumi, Y; Kaji, R; Kunikane, Y; Otomi, Y; Otsuka, H; Sako, W; Shinya, T; Takashi, S; Uyama, N; Watanabe, Y | 1 |
Hikichi, C; Hirota, S; Ishikawa, T; Ito, S; Maeda, T; Mizutani, Y; Murate, K; Mutoh, T; Nagao, R; Niimi, Y; Shima, S; Ueda, A | 1 |
Galleri, G; Madeddu, G; Mulas, A; Nieddu, A; Nuvoli, S; Piras, MR; Rocchitta, G; Serra, PA; Spanu, A | 1 |
Huo, L; Li, F; Wang, H; Xu, D; Zhu, S; Zhu, W | 1 |
Kim, JS; Lee, JE; Lee, KS; Oh, YS; Ryu, DW; Yoo, IR; Yoo, SW | 1 |
Iwabuchi, Y; Jinzaki, M; Matsusaka, Y; Minami, Y; Nakahara, T | 1 |
Agostini, D; Defer, GL; Lamotte, G; Lebasnier, A; Morello, R | 1 |
Cameron, A; Hayhow, B; Middlemost, M | 1 |
Denis, A; Guillaume, L | 1 |
Asakura, K; Fukui, T; Hikichi, C; Hirota, S; Ishikawa, T; Ito, S; Kizawa, M; Mizutani, Y; Murate, K; Mutoh, T; Shima, S; Ueda, A | 1 |
Hattori, N; Li, Y; Takanashi, M | 1 |
Fujishiro, H; Kosaka, K; Ozaki, N; Ukai, K; Watanabe, M | 1 |
Fujita, H; Hirata, K; Miyamoto, M; Miyamoto, T; Numao, A; Suzuki, K; Uchiyama, T; Watanabe, Y | 1 |
Hasegawa, K; Kowa, H; Stoessl, AJ; Wszolek, ZK; Yagishita, S; Yokoyama, T | 1 |
Arai, K; Asahina, M; Funayama, M; Hattori, N; Hattori, T; Kanai, K; Kuwabara, S; Kuwabara, Y; Sekiguchi, Y; Tomiyama, H; Uchiyama, T | 1 |
Chung, EJ; Kim, BJ; Lee, GH; Lee, WY; Yoon, WT | 1 |
Rascol, O; Schelosky, L | 1 |
Diederich, NJ; Fröhlich, I; Pilloy, W; Vaillant, M | 1 |
Buongiorno, M; De la Cerda, A; Ezquerra, M; Gaig, C; Lomeña, F; Martí, MJ; Muxí, A; Navales, I; Paredes, P; Santacruz, P; Tolosa, E; Valldeoriola, F | 1 |
Behnke, S; Dillmann, U; Dorschner, J; Farmakis, G; Fassbender, K; Hellwig, D; Kirsch, CM; Schneider, S; Spiegel, J | 1 |
Antke, C; Beu, M; Müller, HW; Nikolaus, S; Schnitzler, A; Südmeyer, M; Wojtecki, L; Zizek, T | 1 |
Kondo, C; Kusakabe, K; Momose, M; Uchiyama, S; Uchiyama, Y | 1 |
Cason, E; Cocciolillo, F; Di Giuda, D; Fagioli, G; Giordano, A; Stefanelli, A; Treglia, G | 1 |
Kokubo, Y; Kuzuhara, S; Morimoto, S; Nomura, Y | 1 |
Berganzo, K; Gómez-Esteban, JC; Iodice, V; Lezcano, E; Llorens, V; Low, D; Mathias, CJ; Sánchez-Manso, JC; Somme, JH; Tijero, B; Vichayanrat, E; Zarranz, JJ | 1 |
Inoue, M; Inoue, Y; Kishimoto, T; Kiuchi, K; Kosaka, J; Morikawa, M; Norimoto, K | 1 |
Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kametaka, S; Kurata, T; Manabe, Y; Morimoto, N; Ohta, T; Ohta, Y; Sato, S; Takao, Y | 1 |
Ito, M; Iwasaki, Y; Mimuro, M; Mori, K; Yoshida, M | 1 |
Hattori, H; Nakade, S; Orimo, S; Ozawa, E; Takahashi, A; Taki, K; Tsuchiya, K | 1 |
Abo, M; Fukumitsu, N; Hattori, N; Honda, H; Inoue, K; Kono, Y; Kurita, A; Orimo, S; Sengoku, R; Suzuki, M | 1 |
Fukuda, T; Fukumitsu, N; Kajiyama, S; Kiyono, Y; Saji, H; Suzuki, M | 1 |
Choi, YY; Chung, YA; Kim, HT; Kim, J; Kim, JS; Kim, SH; Kim, YI; Lee, KS; Lee, PH; Park, JW | 1 |
Annesi, F; Annesi, G; Bagnato, A; Candiano, IC; Civitelli, D; Condino, F; D'Amelio, M; Loizzo, P; Morelli, M; Morgante, L; Nicoletti, G; Novellino, F; Petrone, A; Quattrone, A; Rocca, FE; Savettieri, G; Tarantino, P; Zappia, M | 1 |
Braune, S | 1 |
Fujiwara, H; Maekawa, N; Saito, K; Takatsu, H; Takemura, M; Wada, H | 1 |
3 review(s) available for 3-iodobenzylguanidine and Parkinsonian Disorders
Article | Year |
---|---|
123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.
Topics: 3-Iodobenzylguanidine; Autonomic Nervous System Diseases; Heart; Humans; Lewy Body Disease; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2009 |
MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.
Topics: 3-Iodobenzylguanidine; Diagnosis, Differential; False Negative Reactions; False Positive Reactions; Heart; Humans; Lewy Body Disease; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; ROC Curve | 2012 |
The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.
Topics: 3-Iodobenzylguanidine; Animals; Diagnosis, Differential; Humans; Multiple System Atrophy; Myocardium; Neurodegenerative Diseases; Parkinsonian Disorders; Radiopharmaceuticals | 2001 |
3 trial(s) available for 3-iodobenzylguanidine and Parkinsonian Disorders
Article | Year |
---|---|
Initial Versus Follow-up Sequential Myocardial 123I-MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes.
Topics: 3-Iodobenzylguanidine; Aged; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Male; Myocardial Perfusion Imaging; Parkinson Disease; Parkinsonian Disorders; ROC Curve | 2019 |
MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy.
Topics: 3-Iodobenzylguanidine; Adenosine; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Galvanic Skin Response; Heart; Heart Rate; Humans; Iodine Radioisotopes; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Respiration; Sensitivity and Specificity; Sympathetic Fibers, Postganglionic; Tomography, Emission-Computed, Single-Photon; Valsalva Maneuver | 2009 |
Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Algorithms; Benzamides; Diagnosis, Differential; Humans; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Pyrrolidines; Radionuclide Imaging; ROC Curve; Sensitivity and Specificity; Tropanes | 2011 |
32 other study(ies) available for 3-iodobenzylguanidine and Parkinsonian Disorders
Article | Year |
---|---|
Is 123I-MIBG Scintigraphy Beneficial or Excessive for the Diagnosis of Parkinson's Disease in the Early Phase?
Topics: 3-Iodobenzylguanidine; Aged; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Retrospective Studies | 2019 |
A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis.
Topics: 3-Iodobenzylguanidine; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Humans; Lewy Body Disease; Parkinsonian Disorders; Radionuclide Imaging; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2021 |
Meta-iodobenzylguanidine myocardial scintigraphy in Perry disease.
Topics: 3-Iodobenzylguanidine; Aged; Autonomic Nervous System Diseases; Biomarkers; Depression; Dynactin Complex; Female; Humans; Hypoventilation; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinsonian Disorders; Pedigree; Radiopharmaceuticals | 2021 |
The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinson Disease; Parkinsonian Disorders; ROC Curve; Tomography, Emission-Computed, Single-Photon; Tropanes | 2017 |
Usefulness of combining
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinsonian Disorders; Protein Binding; Retrospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tropanes | 2017 |
123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Brain; Diagnosis, Differential; Female; Heart; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Nortropanes; Parkinsonian Disorders; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2017 |
Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Diagnosis, Differential; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinson Disease; Parkinsonian Disorders; Radiopharmaceuticals; Sensitivity and Specificity | 2018 |
Focal 123I-MIBG Uptake in the Medial Segment of the Normal Liver.
Topics: 3-Iodobenzylguanidine; Aged, 80 and over; Biological Transport; Humans; Incidental Findings; Liver; Male; Parkinsonian Disorders; Single Photon Emission Computed Tomography Computed Tomography | 2019 |
Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses.
Topics: 3-Iodobenzylguanidine; Aged; Brain; Female; Heart; Humans; Lewy Body Disease; Male; Mediastinum; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2015 |
Cardiac (123)I-meta-iodo-benzyl-guanine in a patient with bipolar affective disorder, musical hallucinations and Parkinsonism.
Topics: 3-Iodobenzylguanidine; Atrophy; Bipolar Disorder; Brain; Female; Hallucinations; Heart; Humans; Middle Aged; Music; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed | 2016 |
Cardiac
Topics: 3-Iodobenzylguanidine; Brain; Heart; Humans; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2017 |
Retrospective analysis of parkinsonian patients exhibiting normal (123)I-MIBG cardiac uptake.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Parkinsonian Disorders; Radionuclide Imaging; Retrospective Studies; ROC Curve; Severity of Illness Index | 2015 |
Absence of Lewy pathology associated with PINK1 homozygous mutation.
Topics: 3-Iodobenzylguanidine; Brain; Female; Humans; Lewy Bodies; Magnetic Resonance Imaging; Middle Aged; Mutation; Myocardial Perfusion Imaging; Parkinsonian Disorders; Protein Kinases; Radiopharmaceuticals | 2016 |
Similarity of symptoms between transient epileptic amnesia and Lewy body disease.
Topics: 3-Iodobenzylguanidine; Aged; Amnesia; Anticonvulsants; Cognition Disorders; Electroencephalography; Female; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Myocardial Perfusion Imaging; Parkinsonian Disorders; Piracetam; Seizures; Tomography, Emission-Computed, Single-Photon | 2017 |
Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
Topics: 3-Iodobenzylguanidine; Aged; Diagnosis, Differential; Female; Heart; Humans; Male; Olfactory Perception; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Substantia Nigra; Ultrasonography, Doppler, Transcranial | 2016 |
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Isoleucine; Japan; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Tetrabenazine; Tyrosine | 2009 |
Preserved cardiac (123)I-MIBG uptake and lack of severe autonomic dysfunction in a PARK9 patient.
Topics: 3-Iodobenzylguanidine; Adult; Autonomic Nervous System Diseases; Heart; Humans; Leucine; Male; Myocardium; Parkinsonian Disorders; Phenylalanine; Proton-Translocating ATPases; Radionuclide Imaging; Young Adult | 2009 |
Myocardial MIBG scintigraphy: a useful clinical tool? : A retrospective study in 50 parkinsonian patients.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Diagnosis, Differential; Female; Heart; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinsonian Disorders; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2010 |
123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Glycine; Heart; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Radionuclide Imaging; Radiopharmaceuticals; Serine; Severity of Illness Index; Smell; Statistics, Nonparametric | 2011 |
Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Female; Heart; Humans; Longitudinal Studies; Male; Middle Aged; Motor Activity; Myocardial Perfusion Imaging; Parkinsonian Disorders; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric | 2011 |
Comparison of parameters of (123)I-metaiodobenzylguanidine scintigraphy for differential diagnosis in patients with parkinsonism: correlation with clinical features.
Topics: 3-Iodobenzylguanidine; Aged; Analysis of Variance; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Mediastinum; Myocardium; Parkinsonian Disorders; Radionuclide Imaging; Retrospective Studies; ROC Curve; Sensitivity and Specificity | 2011 |
Cardiac ¹²³I-meta-iodobenzylguanidine scintigraphy in patients with amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula, Japan.
Topics: 3-Iodobenzylguanidine; Aged; Amyotrophic Lateral Sclerosis; Dementia; Female; Humans; Iodine Radioisotopes; Japan; Male; Middle Aged; Myocardial Perfusion Imaging; Parkinsonian Disorders; Radiopharmaceuticals | 2012 |
SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy.
Topics: 3-Iodobenzylguanidine; Aged; Diagnosis, Differential; Female; Heart; Humans; Male; Mediastinum; Middle Aged; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Severity of Illness Index; Supranuclear Palsy, Progressive; Tomography, Emission-Computed, Single-Photon | 2012 |
Parkinsonism with multiple cysts in the bilateral striata.
Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Antipsychotic Agents; Brain Ischemia; Delirium; Delusions; Diagnosis, Differential; Dibenzothiazepines; Dominance, Cerebral; Drug Therapy, Combination; Encephalomalacia; Hallucinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neostriatum; Neurologic Examination; Organophosphate Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced; Quetiapine Fumarate; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2011 |
PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Basal Ganglia; Cerebral Cortex; Cerebrovascular Circulation; Cysteine; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Multiple System Atrophy; Neurodegenerative Diseases; Organotechnetium Compounds; Parkinson Disease; Parkinsonian Disorders; Radiopharmaceuticals; Supranuclear Palsy, Progressive; Tomography, Emission-Computed, Single-Photon | 2011 |
[Decreased myocardial uptake of meta-iodobenzylguanidine in an autopsy-confirmed case of corticobasal degeneration with Lewy bodies restricted to the sympathetic ganglia].
Topics: 3-Iodobenzylguanidine; Aged; Autopsy; Basal Ganglia; Cerebral Cortex; Diagnosis, Differential; Ganglia, Sympathetic; Heart; Humans; Lewy Bodies; Male; Myocardium; Nerve Degeneration; Nerve Endings; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2012 |
[123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Aged; Basal Ganglia; Cerebral Cortex; Diagnosis, Differential; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2003 |
Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report.
Topics: 3-Iodobenzylguanidine; Exons; Humans; Male; Middle Aged; Myocardium; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2005 |
Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Dose-Response Relationship, Drug; Heart; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Myocardium; Norepinephrine Plasma Membrane Transport Proteins; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2006 |
Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Topics: 3-Iodobenzylguanidine; Aged; Aged, 80 and over; Case-Control Studies; Cerebrovascular Disorders; Female; Heart; Humans; Male; Middle Aged; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals | 2006 |
Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Adult; Diagnosis, Differential; DNA Mutational Analysis; Female; Galvanic Skin Response; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Movement Disorders; Myocardium; Oncogene Proteins; Parkinson Disease; Parkinsonian Disorders; Point Mutation; Promoter Regions, Genetic; Protein Deglycase DJ-1; Protein Kinases; Protein Serine-Threonine Kinases; Radiopharmaceuticals; Severity of Illness Index; Surveys and Questionnaires; Tomography, Emission-Computed, Single-Photon; Ubiquitin-Protein Ligases | 2008 |
Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Cells, Cultured; Desipramine; Dopamine Agents; Heart; Iodine Radioisotopes; Mice; Mice, Inbred C57BL; Myocardium; Neurons; Parkinsonian Disorders; PC12 Cells; Radionuclide Imaging; Rats | 2002 |